Valuation: Roche Holding AG

Market Cap 283B 346B 304B 259B 487B 33,421B 495B 3,362B 1,317B 16,374B 1,299B 1,271B 56,675B P/E 2026 *
19.3x
P/E 2027 * 17.6x
Enterprise Value 294B 359B 315B 269B 505B 34,658B 514B 3,486B 1,366B 16,979B 1,347B 1,318B 58,771B EV / Sales 2026 *
4.69x
EV / Sales 2027 * 4.39x
Free-Float
88.78%
Yield 2026 *
2.82%
Yield 2027 * 2.88%
1 day-1.35%
Current month+3.91%
6 months-1.33%
Current year+2.04%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 341B
+0.86%+2.30%+49.71%+158.86% 1,057B
+1.59%+5.37%+55.77%+54.77% 624B
+0.95%+1.95%+36.11%+80.44% 454B
-0.60%+2.95%+36.28%+39.04% 297B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+1.20%+21.61%+60.14% 201B
-1.18%-5.13%+13.87%+60.35% 162B
-0.16%-2.39%-3.23%-34.39% 143B
Average -0.11%+0.12%+22.36%+43.85% 379.49B
Weighted average by Cap. -0.14%+1.10%+35.02%+76.94%

Financials

2026 *2027 *
Net sales 62.63B 76.5B 67.3B 57.42B 108B 7,395B 110B 744B 291B 3,623B 288B 281B 12,540B 65.39B 79.88B 70.27B 59.95B 113B 7,721B 114B 777B 304B 3,783B 300B 294B 13,093B
Net income 14.58B 17.81B 15.66B 13.36B 25.1B 1,721B 25.51B 173B 67.82B 843B 66.92B 65.47B 2,919B 16.34B 19.96B 17.56B 14.98B 28.13B 1,929B 28.6B 194B 76.02B 945B 75.01B 73.39B 3,272B
Net Debt 10.47B 12.79B 11.25B 9.6B 18.02B 1,236B 18.32B 124B 48.71B 606B 48.06B 47.02B 2,096B 3.81B 4.65B 4.09B 3.49B 6.56B 450B 6.67B 45.26B 17.73B 220B 17.49B 17.12B 763B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA